Eliava Phage Therapy Center

What Eliava Phage Therapy Center does

Eliava Phage Therapy Center (EPTC) is a private outpatient medical clinic headquartered at 3 Gotua Street, Tbilisi, Georgia, established in 2001 as the clinical arm of the Eliava Institute of Bacteriophages, Microbiology and Virology — a research institute founded in 1923 by Prof. George Eliava in collaboration with Felix d'Herelle. EPTC specializes in bacteriophage (phage) therapy, using naturally occurring viruses that selectively infect and destroy bacteria as an alternative to antibiotics for patients with antibiotic-resistant infections (including MRSA, VRE, CRE, and ESBL), chronic recurrent infections, or antibiotic intolerance. The clinic operates across eight clinical specialties — Internal Medicine, Urology & Gynecology, Pediatrics, ENT, Surgery, Dermatology, Massage & Physiotherapy, and Laboratory & Diagnostics — and is supported by the vertically integrated Eliava Consortium, which includes the Eliava Institute's century-old phage collection, the Eliava Diagnostic Center (bacteriological analysis and phage sensitivity testing), the Eliava Authorized Pharmacy (compounding under a special Georgian Ministry license), Eliava BioPreparations (manufacturing six standard products plus custom preparations), and the Georgian-American Diagnostic Center (imaging).

The commercial offering is organized around three products: a Local Treatment Course priced at €4,200 covering 10 workdays of in-clinic diagnostics, multidisciplinary consultations, supportive therapies, and take-home phage preparations; a Distance Treatment Course priced at €2,100 covering telemedicine consultations via Doxy.me and international shipment of phage preparations to patients unable to travel; and Custom (Autophage) Preparations at €1,500 per 20 boxes for resistant strains, with 8–12 week lead time and €900 repeat pricing. Telemedicine maintains HIPAA, GDPR, PHIPA/PIPEDA, and HITECH compliance. The go-to-market is direct-to-consumer: patients self-refer, submit bacterial samples for sensitivity testing, and complete intake via the website or social channels (Facebook, Instagram, YouTube, LinkedIn). Distribution reaches globally, with phage preparations shipped to multiple countries via international courier (subject to local import licensing), and marketing amplified by international earned media (BBC, CNN, Stat News, The Atlantic, The Telegraph).

Revenue mechanics are professional-services-based: episodic per-course fees rather than subscriptions, denominated in Euros with cash or bank-transfer settlement. The clinic has 14 employees, is led by Chief Physician Dr. Dea Nizharadze, and has no disclosed funding rounds, external investors, or public financial filings. Parent affiliation with the Eliava Institute and operation within the Eliava Consortium provide a structural moat through the historic phage library and clinical expertise accumulated since 1923, but the business remains a small, privately held specialty medical practice with thin publicly observable financial data.

Name

Eliava Phage Therapy Center

Legal name

Eliava Phage Therapy Center

Website

https://eptc.ge

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

11–50 employees

Short description

Eliava Phage Therapy Center is a private Tbilisi-based outpatient clinic specializing in bacteriophage therapy for international patients with antibiotic-resistant infections, offering local and telemedicine treatment courses plus custom phage preparations.

Ownership category

akta.pro rank

Headquarters

HQ city

Tbilisi

HQ country

Georgia

HQ region

Asia

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Local Treatment Services: Comprehensive in-person treatment course at the Tbilisi clinic including diagnostics, consultations, phage therapy, and supportive services. Priced at 4200 Euro per course.
2. Distance Treatment Services: Telemedicine consultations and phage preparation shipping for patients unable to travel. Priced at 2100 Euro per course.
3. Custom Phage Preparations: Individualized phage preparations for resistant bacteria, priced at 1500 Euro for initial 20 boxes (8-12 week preparation time), 900 Euro for repeat orders

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Eliava Phage Therapy Center provides bacteriophage (phage) therapy as a medical treatment for antibiotic-resistant and chronic bacterial infections. It offers two core treatment programs: an in-person Local Treatment Course at its Tbilisi, Georgia clinic and a Distance Treatment Course delivered via telemedicine with phage preparations shipped internationally. Services span multiple medical specialties and include custom phage preparations, laboratory diagnostics, and supportive physiotherapy.

Product overview

Eliava Phage Therapy Center offers phage therapy as a unified medical service centered on bacteriophage treatment for antibiotic-resistant bacterial infections. The core offerings are two treatment programs: the Local Treatment Course (4,200 Euro, in-person at Tbilisi clinic) and Distance Treatment Course (2,100 Euro, remote). Custom phage preparations are available as an add-on for individualized treatment. The center operates across multiple medical specialties (Internal Medicine, Pediatrics, Urology/Gynecology, ENT, Surgery, Dermatology) and provides integrated support services including laboratory diagnostics, physiotherapy, and massage therapy. All treatments emphasize bacteriophage preparations as the cornerstone of complex medical services.

Differentiator

Problem solved

Functional benefit

Products and services

• Local Treatment Course In-person phage therapy treatment at the EPTC clinic in Tbilisi, Georgia, lasting 10 workdays. Includes registration, primary care consultation, lab work, diagnostic investigations, commencement of phage therapy, multidisciplinary team consultations, supportive services (therapeutic massage, physiotherapy), continuous phage therapy with adjustments, repeat bacteriological analysis, and phages provided for home use. Priced at 4,200 Euro.
• Distance Treatment Course
• Custom Phage Preparations (Autophage)
• Internal Medicine Phage Therapy
• Urology & Gynecology Phage Therapy
• Pediatric Phage Therapy
• ENT Phage Therapy
• Surgical Infections Phage Therapy
• Dermatology Phage Therapy
• Laboratory & Diagnostic Services
• Massage & Physiotherapy

Named customers1 record

Segments6 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature3 records

Partnerships

Seven partnerships are on record, tiered core, major and minor.

• Eliava Institute of Bacteriophages, Microbiology and VirologycoreStrategic or Co-development PartnerParent research institution founded in 1923 by Prof. George Eliava. Provides the foundational phage research, collection, and expertise that EPTC leverages for clinical applications.
• Eliava FoundationcoreStrategic or Co-development PartnerNon-profit organization established by scientists from the Eliava Institute. Part of the Eliava Consortium joint venture.
• Eliava BioPreparationscoreTechnology or IntegrationSpin-off company developing and manufacturing therapeutic and prophylactic bacteriophage preparations. Produces six standard bacteriophage products and custom preparations.
• Eliava Diagnostic Center (Diagnozi 90)coreTechnology or IntegrationEstablished in 1990 by leading Eliava scientists. Provides extensive microbiological and clinical laboratory services including bacteriological analysis and phage sensitivity testing. 36 employees including 12 with state laboratory medicine certificates.
• Georgian-American Diagnostic CentermajorTechnology or IntegrationDiagnostic partner providing MRI, CT, ultrasound, densitometry, and X-ray services with protocols according to American Radiology Association. Images reviewed by American radiologists.
• Eliava Authorized PharmacycoreTechnology or IntegrationPharmacy established in 2013 producing customized bacteriophage preparations. Holds special license from Georgian Ministry for compounding and personalized medications.
• Tourism AgenciesminorChannel Partner/ Reseller/ DistributorPartner agencies providing accommodation (e.g., Ameri Plaza hotel) and airport transfer services for international patients visiting the clinic.

Scale indicators3 records

Recent moves8 records

Expansion highlights6 records

Others

• The Eliava Institute of Bacteriophages, Microbiology and Virology: Parent research institution founded in 1923 that supplies EPTC's phage collection and scientific expertise. Not a direct market competitor but the closest enabling partner; understanding the institute is essential context for evaluating EPTC's moat.

Emerging players

• Eligo Bioscience: France-based biotech developing engineered phage-based precision medicines to target specific bacterial pathogens. Comparable scientific approach to selective bacterial elimination.
• ContraFect: US biotech developing direct lytic agents and phage-derived lysins for serious bacterial infections including MRSA. Comparable in addressing antibiotic-resistant infections though using phage-derived rather than whole phage approaches.
• BiomX: Israel-based clinical-stage company developing phage-based therapies for conditions including cystic fibrosis and IBD. Comparable in therapeutic area and patient target populations.
• Locus Biosciences: US-based clinical-stage company developing engineered phage therapies targeting resistant bacterial infections in the urinary tract and other indications. Comparable therapeutic focus with regulatory pathway approach.
• PhagePro: US-based startup focused on prophylactic and therapeutic phage applications for infectious disease, with research ties to Tufts University. Comparable in clinical phage therapy development pipeline.

Direct peers

• Phagelux: China-based phage therapy company developing both human therapeutic phage products and animal health applications. Direct peer operating in the global phage therapy market.
• Intralytix: US-based phage technology company with FDA-approved phage products for food safety and a clinical pipeline targeting human bacterial infections. Direct peer in therapeutic bacteriophage development.
• Adaptive Phage Therapeutics: US-based clinical-stage phage therapy company developing personalized phage treatments for antibiotic-resistant infections. Closest direct competitor in the personalized phage therapy space, though focused on US regulatory pathways rather than international patient travel.
• TechnoPhage: Portugal-based biotech company developing bacteriophage products for bacterial infections, with focus on respiratory and skin infections. Direct peer in clinical phage therapy development.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCCFS9BH4x9KH2anA-Xz6ZAA
• Facebookfacebook.com/PhageTherapy
• LinkedInlinkedin.com/company/eliava-phage-therapy-center
• Instagraminstagram.com/eliava_phage_therapy_center

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eliava Phage Therapy Center